Shots:

• Prothena is eligible to receive ~$1.2B as development and commercial milestones including $100M as up front and near-term clinical milestones
• Novo Nordisk acquires Prothena’s subsidiary and gets WW rights to the IP and related rights of Prothena’s ATTR amyloidosis business and pipeline. Novo Nordisk will develop the P-II ready Ab PRX004 for ATTR cardiomyopathy
• Prothena has completed a P-I study of PRX004 in patients with hereditary forms of ATTR which showed that the therapy was safe and well tolerated

  Ref: Prothena | Image: Tip Ranks